Legislation To End Surprise Medical Bills Has High Public Support — In Both Parties
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
Showing 41 - 60 of 76
-
-
Investors’ Deep-Pocket Push To Defend Surprise Medical Bills
As lobbyists purporting to represent doctors and hospitals fight attempts to control surprise medical bills, it has become increasingly clear that the force behind the effort is not just medical professionals, but also investors from private equity firms.
By Rachel Bluth and Emmarie Huetteman -
Pharma Cash Rolls Into Congress To Defend An Embattled Industry
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
-
Biden-Harris Debate Rematch Highlights Health Plan Differences
The Wednesday night event marked the second night in a row for Democratic presidential hopefuls to stake claims on how to fix the health care system.
-
In A Messy Democratic Presidential Debate, Facts About ‘Medicare For All’ Get Tossed About
Candidates used their varying views on how to achieve universal coverage — whether through Medicare for All or more incremental steps — as a means to differentiate themselves from the field.
-
Democrats Favor Building On ACA Over ‘Medicare For All’
Asked to choose between building on the Affordable Care Act and replacing it with a national Medicare for All plan, 55% of Democrats and Democratic-leaning independents said they would expand the existing law, according to a Kaiser Family Foundation poll released Tuesday.
-
GOP Senators Distance Themselves From Grassley And Trump’s Efforts To Cut Drug Prices
Even some Republicans who supported a sweeping bipartisan bill to rein in drug costs may not back it in the Senate vote.
-
Summer Setbacks: The Long Road To Lower Drug Prices Hits Some Potholes
Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
-
Pelosi Aims For Feds To Negotiate Drug Prices, Even For Private Insurers
A draft plan spearheaded by House Speaker Nancy Pelosi would allow the federal government for the first time to negotiate prices for 250 drugs for Medicare and apply those prices to all payers, including employers and insurers.
-
Universal Health Care For New Yorkers? Not Exactly
Despite what New York Mayor Bill de Blasio claimed during the first night of the presidential debates, universal health care in the Big Apple is still in the seeding stage.
-
Trump Administration Rule Would Undo Health Care Protections For LGBTQ Patients
Supporters of the rule say it would strengthen health care professionals’ freedom of conscience, but opponents say it “empowers bad actors to be bad actors.”
-
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
-
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
-
Pharma Execs Dig In For A Fight Against Outraged Senators
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
By Emmarie Huetteman and Jay Hancock -
Congress Squares Off With Pharma CEOs In Showdown Over High Drug Prices
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
By Emmarie Huetteman and Jay Hancock -
Ideas To Curb Surprise Medical Bills Percolate With Rare Bipartisan Push
The recent declaration by President Donald Trump that taming unexpected medical bills would be a top priority for his administration echoed through the halls of Congress.
By Shefali Luthra and Emmarie Huetteman -
Congress Wades Into Emotional Debate Over High-Cost Prescription Drugs
Key House and Senate committees kick off hearings on drug prices, and patients’ families weigh in with tragic stories.
By Emmarie Huetteman and Rachel Bluth -
Trump Zeroes In On Surprise Medical Bills In White House Chat With Patients, Experts
Patients and doctors got a chance to share their nightmarish experiences with medical bills with President Donald Trump and other top White House officials.
-
Democrats Winning Key Leadership Jobs Have Taken Millions From Pharma
Top House Republican also received more than $1 million from drugmakers since 2007.
-
Women Applaud Michelle Obama’s Decision To Share Her Trauma Of Miscarriage
The attention may help women understand that miscarriage is common but still not easily talked about.
Sign Up For Our Newsletter
Stay informed by signing up for the Morning Briefing and other emails: